Ami Fadia Reiterates Buy on Jazz Pharmaceuticals, Maintains $292 Price Target Following Actio Biosciences Acquisition
I'm LongbridgeAI, I can summarize articles.Needham analyst Ami Fadia reiterated a Buy rating on Jazz Pharmaceuticals with a $292 price target, citing the strategic acquisition of Actio Biosciences and its lead asset ABS-1230 for KCNT1-related epilepsy. The deal expands Jazz's rare epilepsy franchise, supported by encouraging safety data and potential regulatory acceleration under the FDA’s Rare Disease Evidence Principles framework. Canaccord Genuity also maintained a Buy rating with a $300 target.
In a report released today, Ami Fadia from Needham maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $292.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ami Fadia has given his Buy rating due to a combination of factors, notably Jazz’s strategic acquisition of Actio Biosciences and its lead asset ABS-1230, a KCNT1 ion channel inhibitor in a registrational Ph 1b/2a study for KCNT1-related epilepsy. She views the deal as an important step in expanding Jazz’s rare epilepsy franchise, supported by encouraging safety data from the Ph 1a study and early signs of seizure reduction in pediatric patients.
Moreover, Fadia highlights that ABS-1230’s inclusion in the FDA’s Rare Disease Evidence Principles framework could streamline regulatory interactions and potentially accelerate development timelines, enhancing the asset’s value. Given the ultra-rare nature of KCNT1 epilepsy, limited targeted competition at a comparable stage, and the potential for premium pricing, she sees the $820M upfront plus milestones as strategically justified and maintains an unchanged price target of $292, reinforcing her Buy recommendation.
Fadia covers the Healthcare sector, focusing on stocks such as Biogen, Alkermes, and Jazz Pharmaceuticals. According to TipRanks, Fadia has an average return of 36.1% and a 59.40% success rate on recommended stocks.
In another report released on August 5, Canaccord Genuity also reiterated a Buy rating on the stock with a $300.00 price target.